Cargando…

A pilot study of Ipilimumab in patients with stage IV melanoma receiving palliative radiation therapy

Detalles Bibliográficos
Autores principales:	Knox, Susan, Reddy, Sunil, Hiniker, Susan M, Swetter, Susan, Shura, Lei, Maecker, Holden T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288737/ http://dx.doi.org/10.1186/2051-1426-2-S3-P75

Ejemplares similares

Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab
por: Sodji, Quaovi H, et al.
Publicado: (2020)

Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up
por: Gutkin, Paulina M, et al.
Publicado: (2018)

Predictors of clinical response to immunotherapy with or without radiotherapy
por: Hiniker, Susan M., et al.
Publicado: (2015)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
por: Revicki, Dennis A, et al.
Publicado: (2012)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer
por: Knox, Susan J., et al.
Publicado: (2019)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
por: Feng, Yan, et al.
Publicado: (2014)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
por: Jamal, Rahima, et al.
Publicado: (2017)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

Ipilimumab and Cancer Immunotherapy: A New Hope for Advanced Stage Melanoma
por: Mansh, Matthew
Publicado: (2011)

Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma
por: Andrews, Stephanie, et al.
Publicado: (2012)

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
por: Tarhini, Ahmad A., et al.
Publicado: (2014)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
por: Larkin, James, et al.
Publicado: (2023)

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
por: Ma, Vincent T., et al.
Publicado: (2022)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Fluorescence In Situ Hybridization Analysis of Atypical Melanocytic Proliferations and Melanoma in Young Patients
por: DeMarchis, Emilia H, et al.
Publicado: (2014)

Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020
por: Qian, Mollie F, et al.
Publicado: (2022)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
por: Cavalcante, Ludimila, et al.
Publicado: (2015)

Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
por: Moreira, Raphael B., et al.
Publicado: (2017)

Ipilimumab for advanced melanoma: A pharmacologic perspective
por: Trinh, Van Anh, et al.
Publicado: (2013)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Emerging options for the treatment of melanoma – focus on ipilimumab
por: Roddie, Claire, et al.
Publicado: (2014)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)
por: Lapointe, Réjean, et al.
Publicado: (2015)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s1e225oae76p9dqvspl27dtknt